Stop the pain: Tips for increasing patient retention and decreasing missing data in analgesia clinical trials
Rho
| « Previous month | Next month » |
Dutch drug delivery and development company OctoPlus is withdrawing its follow-on financing on its five-strong product portfolio in response to the US mortgage crisis and the struggling stock market.
Indian pharma services provider Jubilant Organosys is looking to buy up European contract research organisations (CRO) and contract research and manufacturing services (CRAMS) and it has got $100m to spend, according to a report in The Economic Times.
Specialty pharmaceutical company Akorn has signed up with India-based Cipla in an exclusive manufacturing and supply agreement for an undisclosed inhaled drug.
Dr Reddy's, China Aoxing Pharmaceutical, Cook Pharmica and Alpha Biologics have all recently announced contract manufacturing news.
Xenome, which specialises in extracting therapeutic peptides from the venom of poisonous animals has penned a deal with Amylin Pharmaceuticals to find drugs that tackle metabolic diseases such as diabetes and obesity.
PolyTherics has been boosted with £350,000 ($723,135) in funding to explore the development and production of long-lasting therapeutic antibody fragments.
GVK Bio has reinforced its claim to be India's top contract research organisation with a 100-crore ($25m) push from a private investment company. The funds will be used to expand its drug discovery services and push further into preclinical and clinical development.
Japanese drugmaker Astellas has agreed to acquire US biotech firm Agensys as part of its plan to ramp up antibody research, especially in the field of cancer.
Sanofi-Aventis is to build a new influenza vaccine manufacturing facility in China.
Singapore's biomedical manufacturing output was down again over October, stunting growth for the region's entire manufacturing sector.
In this week's review of activity within the preclinical research services arena, news has emerged involving ChemDiv, SRI International, ShangPharma, Ranbaxy and Xceleron.
The US Food and Drug Administration has allowed Targeted Genetics to restart testing its arthritis gene therapy after deciding the drug wasn't at fault when one person died in the original clinical trial.
The pharmaceutical industry is backward when it comes to outsourcing, industry experts said at the American Association of Pharmaceutical Scientists (AAPS) conference in San Diego last week.
Merck & Co. and its partner Vertex Pharmaceuticals have stopped enrolling cancer patients to the clinical trial of its aurora kinase trial after one patient suffered heart problems.
Boehringer Ingelheim has added to its contract services with the manufacture, fill and finish capacity for drugs in prefilled syringes.
Recipharm has come to rescue of UK-based Ashton Pharma, which has been nervously awaiting to discover its fate, having spent five months in administration after its former owners Inyx Inc. suffered major financial woes.
FMC BioPolymer has introduced two new excipient products to the pharma market - the first in two years.
The discovery of a new molecule that can act as a brake for the immune system could lead to new therapies for cancer and autoimmune diseases such as diabetes.
The latest in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators.
New research from Frost & Sullivan provides a snapshot of biopharma spending trends on contract research organisations (CROs), along with forecasts for industry growth.
A startling breakthrough has allowed scientists to create human stem cells from just reprogrammed skin cells, with no embryo and thus, perhaps no ethical dilemma.
Covance has acquired a partially constructed facility from Eli Lilly and plans to invest $175m (€118m) to convert it into a drug development laboratory to meet demand from its biopharmaceutical customers.
Pfizer's revelation this week that it plans to slice jobs in Puerto Rico is the latest in a string of blows for this popular offshore manufacturing location.
A supercomputer designed to root out genes that have been conserved over millions of years of evolution has discovered 300 new human genes.
While India, the Asia-Pacific, Eastern Europe and Latin America are all gaining recognition as potential new hot spots, South Africa remains 'underutilised as a clinical trial destination,' according to a prominent industry figure.
Researchers at Randox, UK, have developed a biochip that enables the simultaneous measurement of 12 human cytokines from human serum samples enabling cytokine studies to be conducted faster.
Merck & Co. has turned to India's Nicholas Piramal (NPIL) for its latest research collaboration, as the preclinical offshoring trend persists.
Contract manufacturer Aesica has confirmed reports of a blast at its Ponders End facility in North London last night, hospitalising three workers.
United Drug has continued this year's shopping spree, snapping up a UK pharmaceutical conference services firm.
Cambridge Major Laboratories (CML) has bought up a Dutch supplier of active pharmaceutical ingredient (API) development services, creating one of the largest pharma chemistry development organisations in the western hemisphere.
Scientists have discovered that a protein called cystatin C can prevent damaging Alzheimer's plaques from forming by keeping their constituent protein water soluble.
AstraZeneca, Encorium, Icon and Eden Biodesign have all had people on the move in the world of pharmaceutical outsourcing.
Raven Biotechnologies have announced positive initial clinical trial results for their anticancer antibody that causes tumour cells to swell up and die.
Contract pharmaceutical development company Azopharma has carved out its drug delivery segment into a new company, APIcross Drug Delivery Technologies.
Russia's clinical trials industry appears to be making a gradual recovery from a setback earlier this year when the government imposed an unexpected ban on biologic exports.
PolyPeptide Laboratories Group is to acquire the peptide manufacturing group NeoMPS.
Workers at Johnson & Johnson's (J&J's) Belgium subsidiary went on strike today in protest at the compensation being offered to those at the firm falling foul of the dreaded pharma axe.
Celgene has agreed to pay $2.9bn for Pharmion in the hope of becoming a 'global leader in the haematology and oncology field', but do the company's pipelines match up well together?
Caliper Life Sciences has launched new testing services that will help researchers weed out unsuitable combination drug therapies in the preclinic.
Celesio fingerpointed two 'extraordinary items' in its dominant Wholesale division for the drag on company profits during the third quarter.
Researchers have uncovered some of the underlying causes of lupus, and have even suggested certain targeted therapies to tackle the autoimmune disease.
The latest in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators.
PRA International continues to see its profits ebb away but will soon face less financial scrutiny as it nears a handover of ownership into private hands.
The US Food and Drug Administration (FDA) has given stakeholders an extra month to get their views in on scrapping epinephrine inhalers containing CFCs.
In this week's review of activity within the preclinical research services arena, news has emerged involving GATC Biotech, NextGen Sciences and Genedata.
The man often credited with causing Biogen Idec to be put up for sale, billionaire corporate raider Carl Icahn, has invested in Genzyme and promptly started industry tongues wagging about a takeover.
Albany Molecular Research Inc (AMRI) recently turned in Q3 results, posting figures buoyed by continued demand for its pharmaceutical development services.
Evotec's bid to distance itself from being a services business and eventually morph into a fully fledged pharma company has been felt on the company's balance sheet during the third quarter.
Pfizer yesterday announced a multi-million dollar pay-off to ex-partner Nektar Therapeutics, but the details of the deal reveal not only Nektar's concerns for its future, but also that Pfizer is still keeping its fingers in the Exubera pie.
Accelrys is offering its SciTegic scientific operating system to academics for free to enable them to create software applications and share them with both academic and commercial communities.
In the latest twist in Roche's fight to acquire diagnostics expert Ventana, the companies have signed a confidentiality agreement that will enable the pharma giant access to Ventana's books.
Outsourcing-Pharma tracks the latest eClinical movements, featuring Phase Forward, Nextrials, Octagon and Omnicare.
BioCryst's recent clinical trials debacle highlights the importance of the robust and realistic design of, and careful adherence to, a drug trial protocol.
Canadian contract manufacturer PharmEng recently announced that its new specialised manufacturing facility in Nova Scotia is open for business.
As of next year Chinese pharmaceutical manufacturers will face a tougher time gaining good manufacturing practice (GMP) certification after the country's regulator signalled new and stricter standards were on the way.
NPIL Pharma last week told workers at its former Pfizer plant in Morpeth, UK that the company is considering hiving off jobs in a bid to maintain the site's viability.
An analyst report released yesterday identified AstraZeneca as being in 'serious trouble' and branded it as potentially the 'worst [large cap] performer in [the] entire sector' over the next eight years.
A small molecule version of a protein called Smac can turn the survival signal for a variety of tumour cells into a death signal and could be effective as a new class of drug, especially for lung cancer patients.
A new 3D model of the human liver that even has its own blood supply could pump new life into drug safety tests by predicting problems earlier and cut down on animal experiments.
Talks between World Health Organization (WHO) member states and the drug industry over how to narrow the health gap between rich and poor countries have stalled.
China's second largest contract research organisation (CRO) ShangPharma has attracted $30m (€21m) from US private investment firm TPG as the Asian pharma market continues to simmer.
Tripos Discovery Research (TDR) has risen from the ashes surrounding the liquidation of its previous owners Tripos, Inc. to land a 'library enrichment' deal with Schering-Plough.
AstraZeneca's axe has made its latest appearance in South Africa, with the sale of a packaging plant and the formation of an outsourcing deal with its new owners.
Management of publicly-traded Synexus have agreed to the £18.1m (€25.7m) sale of the company to a private equity firm that has promised to fund its global expansion ventures.
German chemicals firm BASF has announced a major price hike across its range of pharmaceutical excipients, upping price tags by as much as 9 per cent.
Biopharmaceutical contract manufacturer Wacker will be expanding its German facility in Jena for €15m ($22m) as it meets demand for biologics.
After losing a key Novartis contract and getting caught up in the Inyx collapse, Inventiv Health had good news this week when it reported its third quarter results.
The latest in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators.
INC Research, Quintiles, Bridge Pharmaceuticals, Charles River Laboratories and PharmaNet have all had people on the move in the world of pharmaceutical outsourcing.
NanoImaging Services has opened what it claims is a first of its kind fee-for-service imaging business to enable structural characterisation and validation of biological drugs throughout the development pipeline.
Merck & Co's failed HIV vaccine may actually increase the risk of infection and the latest data raises questions over whether the cold virus used as a delivery technique was at fault.
West Pharmaceutical Services, one of the two firms responsible for manufacturing Pfizer's failed Exubera device, recently turned in its third quarter financials, so far avoiding any major dent from the company's decision to drop the inhalable insulin product.
This week two sets of contract research organisations (CROs) have announced plans to link arms in order to spread their reach further into this increasingly globalised marketplace.
US-based Aveo Biopharmaceuticals is hoping to prove its R&D strategy can buck high industry failure rates when trying to design new cancer drugs and it seems to be working after its lead drug has passed a first-in-man trial with flying colours.
DSM's third quarter financial results are paving the way for the company's transition to a life sciences and material sciences company.
A new Belgian company has joined the throng of pharmas tapping into the booming drug delivery business, but claims that its unique technologies will carve it a place as one of the industry's key players.
Merck & Co has inked a deal potentially worth over $507m (€346m) with GTx over a new class of drugs to treat muscle loss conditions, especially those caused by cancer.
A new report highlights a number of worrying trends emerging in regard to the increasing number of fake pharmaceuticals infiltrating supply chains around the globe.
In this week's review of activity within the preclinical research services arena, new deals have emerged involving MDS Pharma Services, Bruker Biospin and Expression Analysis.
PharmaNet has made a strong comeback during its third quarter after previously slipping into the red and recorded its highest revenue to date - $99.8m (€70.0m).
AstraZeneca's CEO has said the company will stop research in a number of diseases as it continues to cut costs and restructure in the face of falling sales.
Bioserv Corporation, Mikart, Laureate Pharma, Cenexi and Lonza have all recently announced new contract manufacturing news.
Icon has improved its financial position significantly during its third quarter, while its smaller US rival Kendle saw its profit slip again, weighed down by charges from a 2006 acquisition.
It was supposed to keep Pfizer at the top of the cardiovascular drug tree, but when torcetrapib failed, other pharma firms developing similar drugs looked on nervously to see if their drugs were also doomed. A new study suggests they might have nothing to worry about.
UK biopharmaceutical firm Apitope has developed a vaccine that could halt multiple sclerosis in its relentless march to destroy nerve cells.
Charles River Laboratories sailed through its third quarter, with comfortable gains in both revenue and profits.
A US government audit has confirmed the Food and Drug Administration's (FDA's) continual lack of inspection of foreign drug manufacturing plants.
Japan will only be receiving 50 per cent of its usual supply of the blockbuster flu drug Tamiflu (oseltamivir) this year, thanks to significantly reduced demand following reports of suicidal behaviour in adolescents taking the medication.
BioInvent and ThromboGenics' new anticancer antibody is poised to enter clinical trials and could prove a serious rival to VEGF-blocking drugs, due to fewer side-effects and less drug resistance.
Quintiles has bought a contract research organisation (CRO) in Central America to extend its reach in this emerging clinical trials region.
Sigma-Aldrich has continued its push into the RNAi field with the launch of its new mirPremier miRNA (microRNA) isolation kit that promises to speed up miRNA preparation while removing all large, unwanted RNA.
A proposed pilot programme to divert Afghanistan's infamous and illegal opium supply for legal use in analgesics has been backed by the European Parliament but is facing fierce criticism elsewhere.
When it comes to choosing between anti-blood clot medicines, clinicians could be stuck between a rock and a hard place following mixed trial results for Eli Lilly's prasugrel.
For the first time, scientists have found a way to target viral antigens deep inside a cancer tumour, and the result is a new therapy that could treat or even prevent the disease.
Just a day before they were due to come into force, GlaxoSmithKline has won a court case to block controversial changes to patent rules.
Parexel has seen its profits remain perky during its first financial quarter of 2008.
Outsourcing-Pharma.com compiles the news that featured in the clinical contract community of late, involving PPD, Novotech and Generex.
An update to the contract negotiation system for hospital-based clinical trials has come into play in the UK - in a further effort to take some of the pain out of the process and speed up trial start-up times.
| « Previous month | Next month » |